A Phase 2b to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With ACPA-Positive Rheumatoid Arthritis

Prior treatment

• Have received rituximab and experienced insufficient efficacy or loss of efficacy.
• History of any chronic inflammatory arthritis with onset prior to age 18 or history of acute inflammatory joint disease of different origin from RA
• Used any nonimmunosuppresive Fc-based therapeutic protein (e.g., mAb or Fc-fusion protein) within 4 weeks prior to or at screening visit.
• Used any anti-FcRn treatment within 2 months prior to or at Screening Visit or have a documented history of non-response to prior anti-FcRn treatment

Other illness

• Active malignancy or history of malignancy within 5 years prior to screening visit
• Medical history of primary immunodeficiency, T cell or humoral, including common variable immunodeficiency.

• Have a diagnosis of ‘definite RA’ according to the 2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria
• Greater than or equal to 6/68 TJC and ≥ 6/66 SJC at both Screening and Baseline visits.
• C-reactive protein ≥ upper limit of normal (ULN) at screening visit
• Elevated immunoglobulin G (IgG) + ACPA as the Screening Visit.
• Inadequate response to at least 2 classes of biologic/targeted synthetic DMARDs